Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

694
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
694
Neural Regulation01:37

Neural Regulation

41.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
41.1K
Brainstem01:19

Brainstem

4.1K
The brainstem, located inferior to the brain and superior to the spinal cord, serves as a bridge between the cerebrum and the spinal cord. It plays a vital role in relaying information and controlling critical life functions. It comprises three primary regions: the midbrain, pons, and medulla oblongata.
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
4.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.2K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.2K
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

735
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
735

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Cortical Correlates of Gait Compensation Strategies in Parkinson Disease.

Annals of neurology·2022
Same author

Does Ethnicity Influence Recruitment into Clinical Trials of Parkinson's Disease?

Journal of Parkinson's disease·2022
Same author

Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study.

Movement disorders : official journal of the Movement Disorder Society·2022
Same author

Aerobic Exercise Alters Brain Function and Structure in Parkinson's Disease: A Randomized Controlled Trial.

Annals of neurology·2021
Same author

Rapid Dynamic Naturalistic Monitoring of Bradykinesia in Parkinson's Disease Using a Wrist-Worn Accelerometer.

Sensors (Basel, Switzerland)·2021
Same author

Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach.

NPJ Parkinson's disease·2021
Same journal

Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.

Lancet (London, England)·2026
Same journal

Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Nov 9, 2025

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.9K

La enfermedad de Parkinson

Bastiaan R Bloem1, Michael S Okun2, Christine Klein3

  • 1Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Centre of Expertise for Parkinson and Movement Disorders, Nijmegen, Netherlands.

Lancet (London, England)
|April 13, 2021
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de Parkinson es una condición neurodegenerativa creciente con causas y presentaciones complejas. El manejo personalizado y la atención multidisciplinaria son clave, aunque los tratamientos actuales manejan los síntomas, no la progresión.

Más Videos Relacionados

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.5K

Videos de Experimentos Relacionados

Last Updated: Nov 9, 2025

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

1.9K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.1K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.5K

Área de la Ciencia:

  • Neurología
  • Enfermedades neurodegenerativas
  • La genética

Sus antecedentes:

  • La enfermedad de Parkinson (EP) es un trastorno neurodegenerativo complejo con una prevalencia global cada vez mayor.
  • Mientras que el 3-5% de los casos de EP son monogénicos, 90 variantes de riesgo genético contribuyen al riesgo hereditario.
  • Los factores de riesgo incluyen antecedentes familiares, estreñimiento y no ser fumador, cada uno de los cuales duplica potencialmente el riesgo de EP.

Objetivo del estudio:

  • Para proporcionar una visión general de la enfermedad de Parkinson.
  • Destacar la importancia de las estrategias de gestión personalizadas.
  • Para discutir los criterios de diagnóstico actuales, los síntomas no motores y la fase prodromica.

Principales métodos:

  • Diagnóstico clínico basado en bradicinesia con temblor en reposo o rigidez.
  • Reconocimiento de las presentaciones clínicas multifacéticas, incluidos los síntomas no motores.
  • Revisión de los factores genéticos, las asociaciones de riesgo y el asesoramiento pronóstico.

Principales resultados:

  • El diagnóstico se basa en la presentación clínica; las pruebas auxiliares son para casos atípicos.
  • Un largo período prodrómico precede a la manifestación clínica de la enfermedad de Parkinson.
  • La levodopa sigue siendo el tratamiento sintomático de primera línea, haciendo hincapié en la atención multidisciplinaria.

Conclusiones:

  • El manejo óptimo de la enfermedad de Parkinson requiere un enfoque personalizado y multidisciplinario.
  • Ninguna terapia actual detiene la progresión de la enfermedad, pero la investigación en tratamientos modificadores de la enfermedad está en curso.
  • Comprender los subtipos de la enfermedad y la fase prodromica es crucial para futuros avances terapéuticos.